A comprehensive view of liver / kidney / bladder health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.
AstraZenica's Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase 3 trial
Published:
April 16, 2024
by AstraZeneca AB
|
AstraZeneca's IMPACT CKD model predicts chronic kidney disease could impact up to 16.5% of population across US, Brazil, UK, Spain, Germany, Netherlands, China, and Australia by 2032; advanced stages could increase by 59.3%
Published:
April 15, 2024
by AstraZeneca AB
|
Olympus reports positive policy changes by commercial payers is extending coverage for iTind, its minimally invasive treatment for benign prostatic hyperplasia; policy updates may affect up to 27 million enrollees in the US
Published:
April 15, 2024
by Olympus America Inc.
|
CA ACR173: APOL1-Mediated Kidney Disease (AMKD) Awareness Day.
Published:
April 09, 2024
by California 2023-2024 Session
|
Haemonetics receives FDA 510(k) clearance for its TEG 6s Global Hemostasis-HN assay cartridge, expanding its testing capabilities to include fully heparinized patients undergoing cardiovascular surgeries or liver transplants
Published:
April 05, 2024
by Zack's Commentary
|
Ask us about our Consumer Wellness market view